Triple Negative Treatments

Interestingly, triple negative breast cancer (ER/PR/HER2 negative) is more than one disease. While some subsets reveal exquisite sensitivity to drugs like Cisplatin, other tumors may have features that render them better targets for agents that inhibit signaling pathways like AKT/mTOR. There may be other triple negatives for whom androgen therapy could hold benefit. Our experience with the Cisplatin/Gemcitabine doublet in this group, a regimen that we originally developed (Nagourney et al, J Clin Oncol 2000) is one example of good outcome with a appropriately selected chemotherapy. Interestingly, triple negative breast cancer (ER/PR/HER2 negative) is more than one disease. While some subsets reveal exquisite sensitivity to drugs like Cisplatin, other tumors may have features that render them better targets for agents that inhibit signaling pathways like AKT/mTOR. There may be other triple negatives for whom androgen therapy could hold benefit. Our experience with the Cisplatin/Gemcitabine doublet in this group, a regimen that we originally developed (Nagourney et al, J Clin Oncol 2000) is one example of good outcome with a appropriately selected chemotherapy.

This is a very controversial topics. Triple negative breast cancer does not mean automatically chemotherapy. The very very small tumors with no lymph node many not have an indication of chemotherapy depending on the patient's general health condition or age. So question is what is small small? This is where split opinions do exist. This is something that we can not truly discuss unless we see each case in the clinic. This is a very controversial topics. Triple negative breast cancer does not mean automatically chemotherapy. The very very small tumors with no lymph node many not have an indication of chemotherapy depending on the patient's general health condition or age. So question is what is small small? This is where split opinions do exist. This is something that we can not truly discuss unless we see each case in the clinic.